1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Hunan Hansen Pharmaceutical Co., Ltd. Class A

Hunan Hansen Pharmaceutical Co., Ltd. Class A

SSZSE:002412
7.58
CNY
-0.05
(-0.66%)
0.56EPS
9.90P/E
2.77BMarket Cap
Hunan Hansen Pharmaceutical Co., Ltd. Class A
SZSE:002412
(Shenzhen Stock Exchange)

Recent

price

7.58

P/E

ratio

9.90

div

yld

4.00%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.77
0.8
0.97
1.98
2.49
2.64
2.7
2.8
1.83
1.76
1.47
1.77
1.82
1.9
2
2.06
2.01
Revenue per Share
0.14
0.12
0.16
0.37
0.38
0.31
0.25
0.33
0.28
0.32
0.21
0.27
0.33
0.41
0.44
0.39
0.56
Basic EPS, GAAP
0.04
0.03
-0.04
-0.11
0.04
-0.04
0.39
0.19
0.3
0.26
0.07
-0.03
0.26
0.28
0.24
0.47
- -
Free Cash Flow per Basic Share
- -
0.15
- -
- -
0.26
0.01
0.01
0.55
0.03
0.02
0.09
0.01
0.01
0.31
0.01
- -
0.3
Dividend per Share
1.79
1.76
1.92
2.14
2.23
2.42
2.5
2.42
2.71
3.04
3.17
3.46
3.76
3.9
4.38
4.73
4.65
Book Value per Share
1.76
1.72
1.87
1.57
1.68
1.89
1.99
1.93
2.23
2.68
2.88
3.27
3.67
3.81
4.29
4.65
4.57
Tangible Book Value per Share
449
500
504
296
296
296
296
296
503
503
503
503
503
503
503
503
503
Basic Weighted Avg Shares
343
401
489
585
737
781
798
830
922
887
741
892
916
956
1,004
1,039
1,014
Sales/Revenue/Turnover
17.1
13.64
16.1
20.01
17.77
13.81
11.56
15.49
16.16
21.98
13.03
14.49
15.3
18.59
24.14
23.28
24.03
Operating Margin (%)
8
9
9
10
35
39
42
44
46
48
50
51
52
51
41
41
- -
Depreciation Expense
62
59
81
111
112
93
74
98
141
160
106
135
168
205
220
198
279
Net Income, GAAP
15.14
15.41
15.41
15.12
15.18
15.4
16.31
15.81
11.53
14.19
9.76
10.04
7.83
9.29
12.86
16.97
13.52
Effective Tax Rate (%)
18.06
14.68
16.64
18.95
15.16
11.86
9.28
11.83
15.27
17.99
14.32
15.12
18.3
21.46
21.93
19.07
27.57
Profit Margin (%)
816
778
769
466
452
530
85
35
74
257
254
184
485
541
805
1,033
1,093
Working Capital
- -
- -
- -
40
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
899
884
965
1,108
1,153
1,253
1,259
1,219
1,363
1,530
1,595
1,742
1,894
1,963
2,203
2,381
2,341
Total Equity
10.06
6.48
8.58
10.31
9.33
7.26
5.03
6.5
8.86
9.49
6.14
7.39
8.9
10.39
10.1
8.36
12.04
Return on Invested Capital (%)
11.29
6.87
8.86
10.49
9.72
7.57
5.47
7.14
9.57
10.06
6.45
7.72
8.81
10.23
10.24
8.44
12.15
Return on Capital (%)
11.5
6.6
8.81
10.86
10.18
7.92
5.98
7.92
10.9
11.04
6.79
8.08
9.22
10.63
10.57
8.64
12.33
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
58
51
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
503
503
503
Market Capitalization
3,226
3,356
2,768

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,322
1,378
1,172
Cash, Cash Equivalents & STI
583
571
442
Accounts Receivable, Net
282
362
300
Inventories
208
215
221
Total Current Liabilities
288
287
79
Payables & Accruals
- -
- -
- -
ST Debt
58
51
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.75%
8.38%
8.06%
Free Cash Flow
-196.38%
-189.72%
96.63%
Net Income, GAAP
10.68%
14.21%
-10.05%
Sales/Revenue/Turnover
3.29%
7.18%
3.41%
Total Cash Common Dividend
1,075.51%
688.72%
-32.37%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
254
226
214
310
1,004
2025
269
240
- -
298
1,039
2026
263
213
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.08
0.06
0.18
0.44
2025
0.02
0.11
- -
0.23
0.39
2026
0.08
0.14
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
- -
2026
- -
0.3
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Hunan Hansen Pharmaceutical Co., Ltd. is a China-based pharmaceutical company principally engaged in the research, development, manufacture, and sales of traditional Chinese medicine preparations, chemical medicines, and medical preparations. Its main products include Simotang oral liquid for abdominal distention and phlegmatic abdominalgia; Yushangling capsules for injuries from falls; Yinxingye capsules targeting stroke and chest distress; Suoquan capsules for kidney deficiency; as well as ginkgo biloba capsules, Tianma Xingnao capsules, Baibeiyi lung capsules, bitter ginseng capsules, glucamine injections, and various other tablets, capsules, granules, syrups, tinctures, pills, and injections. The company provides a broad range of dosage forms including injections, mixtures, tablets, capsules, granules, syrups, decoctions, tinctures, and pills. It serves both domestic Chinese markets and international markets from its headquarters in Yiyang, Hunan Province, China. Founded in 1998, the company operates as a high-tech enterprise recognized for its pharmaceutical manufacturing capabilities. In recent developments, Hunan Hansen Pharmaceutical renewed its drug production license with regulatory authorities in Hunan Province. The company has also obtained drug registration certificates for new chemical drugs, including Englitazone tablets used in type 2 diabetes treatment, reflecting expansion in its pharmaceutical product portfolio beyond traditional Chinese medicine. It continues to expand its market presence for its key products such as Simotang oral liquid, while planning to build a modern botanical medicine brand focusing on products like Tianma Xingnao capsules. The company achieved revenue growth and improved profitability in the first three quarters of 2024, with a year-on-year revenue increase and a net income rise of over 19%, demonstrating operational growth despite some fluctuations in earnings. Recent honors include recognition as a National High-tech Enterprise and various industry quality and brand awards. The company remains committed to developing new products that leverage traditional Chinese medicine advantages alongside suitable chemical medicines for evolving disease spectrums in China and abroad. Hunan Hansen Pharmaceutical targets industries including gastroenterology, orthopedics/traumatology, cardiovascular and cerebrovascular diseases, operating primarily in China with growing international reach. It employs over 1,500 staff and emphasizes R&D, production scale, and diversified pharmaceutical offerings. Major product categories include traditional Chinese medicinal oral liquids, capsules, injections, and chemical pharmaceutical products. The corporate strategy involves strengthening proprietary Chinese medicine brands and screening biomedicine industry projects for future growth.